Dose Titration of Propofol for Tracheal Intubation in Children With Sevoflurane Inhalation Induction

This study has been completed.
Information provided by (Responsible Party):
Yonsei University Identifier:
First received: March 5, 2010
Last updated: February 17, 2014
Last verified: February 2014
Dose titration of propofol for tracheal intubation in children with sevoflurane inhalation induction.

Condition Intervention
Pediatric Urinary Disorders
Drug: propofol

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Supportive Care
Official Title: Dose Titration of Propofol for Tracheal Intubation in Children With Sevoflurane Inhalation Induction

Resource links provided by NLM:

Further study details as provided by Yonsei University:

Primary Outcome Measures:
  • Assessment of intubation conditions [ Time Frame: 30 minutes after the surgery ] [ Designated as safety issue: No ]

    Assessment of intubation conditions (vocal cord, intubation condition, cough, movement) , peri-induction HR and BP change, post-operative agitation socre at recovery room. ED50 and ED 95 of each group by uring Dixon's up and down methods.

    peri -induction period -comparison of above factors among each groups (GroupA: ETSevo 3vol%, Group B: ETSevo 3.5vol%, Group: ET Sevo 4vol%)

Enrollment: 50
Study Start Date: November 2009
Study Completion Date: March 2011
Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: propofol Drug: propofol
intravenous propofol with sevoflurane inhalation induction


Ages Eligible for Study:   6 Months to 5 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Pediatric patients scheduled for elective day case surgery were enrolled.

Exclusion Criteria:

  • History of obstructive sleep apnea
  • Evidence of cardiorespiratory disease
  • Those who were obese or allergic to any of the anesthetic agents in this study
  • Those with an anticipated difficult airway, full stomach
  • History of malignant hyperthermia or other myopathy were excluded.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01084031

Sponsors and Collaborators
Yonsei University
Principal Investigator: Hae Keum Kil Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, Korea
  More Information

Responsible Party: Yonsei University Identifier: NCT01084031     History of Changes
Other Study ID Numbers: 4-2009-0470 
Study First Received: March 5, 2010
Last Updated: February 17, 2014
Health Authority: Korea: Food and Drug Administration
Korea: Ministry for Health and Welfare

Additional relevant MeSH terms:
Anesthetics, General
Anesthetics, Inhalation
Anesthetics, Intravenous
Central Nervous System Depressants
Hypnotics and Sedatives
Physiological Effects of Drugs
Platelet Aggregation Inhibitors processed this record on May 22, 2016